Jack Mardekian, PhD

home / authors / jack-mardekian-phd

Articles

Economic Outcomes of Warfarin Discontinuation Among Patients with Atrial Fibrillation

Christina A. Spivey, PhD;Xianchen Liu, MD, PhD;Yanru Qiao, MS;Jack Mardekian, PhD;Robert B. Parker, PharmD;Hemant Phatak, PhD;Cristina Masseria, PhD;Sumesh Kachroo, PhD;Younos Abdulsattar, P

August 18th 2016

This study seeks to determine the economic effects of warfarin discontinuation in patients with nonvalvular atrial fibrillation.

Understanding Predictors of Opioid Abuse: Predictive Model Development and Validation

Robert Dufour, PhD;Jack Mardekian, PhD;Margaret K. Pasquale, PhD;David Schaaf, MD;George A. Andrews, MD, MBA, CPE, FACP, FACC, FCCP;Nick C. Patel, PharmD, PhD, BCPP

October 21st 2014

This study developed and tested predictive models of opioid abuse using Humana commercial membership data that were subsequently tested in the Truven commercial data set.

Therapeutic and Subtherapeutic Dosing of Pregabalin: Medication Adherence, Healthcare Resource Utilization, and Costs

Robert J. Sanchez, PhD;Jack Mardekian, PhD;Andrew G. Clair, PhD;Joseph C. Cappelleri, PhD, MPH

August 2nd 2012

Therapeutic and subtherapeutic doses of pregabalin were compared to ascertain differences in adherence, healthcare resource use, and cost between the cohorts.